Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.45 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.45 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15328340 | 0.98 | LMNA (0.58) | LMNAPOLBGAAHTTMEN1 | |
| SCHEMBL18397964 | 0.85 | GAA (0.60) | LMNAPOLBGAAKMT2ATP53 | |
| SCHEMBL9017973 | 0.80 | POLB (0.51) | LMNAPOLBGAAHTTMEN1 | |
| SCHEMBL18397975 | 0.78 | POLB (0.52) | LMNAPOLBGAAHTTTP53 | |
| SCHEMBL10304326 | 0.76 | CYP2C9 (0.60) | HTTMEN1KMT2ARECQL | |
| SCHEMBL18397973 | 0.76 | LMNA (0.50) | LMNAGAATP53CNR1CNR2 | |
| SCHEMBL6553709 | 0.76 | HTT (0.64) | LMNAPOLBGAAHTTMEN1 | |
| SCHEMBL18397965 | 0.75 | HTT (0.44) | GAAHTTMEN1KMT2ACNR1 | |
| SCHEMBL18397969 | 0.75 | LMNA (0.46) | LMNAGAATP53CNR1CNR2 | |
| SCHEMBL27968346 | 0.75 | GAA (0.70) | LMNAGAATP53PTGS1KCNK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9108936-B2 | Substituted 4-aminobenzamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2015-08-18 | — | — | US | disclosed |
| EP-2844645-A1 | SUBSTITUTED 4-AMINOBENZAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2015-03-11 | — | — | EP | disclosed |
| WO-2013156155-A1 | SUBSTITUTED 4-AMINOBENZAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2013-10-24 | — | — | WO | disclosed |
| US-20130281452-A1 | SUBSTITUTED 4-AMINOBENZAMIDES AS KCNQ2/3 MODULATORS | GRUENENTHAL GMBH (DE) | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281452-A1 | SUBSTITUTED 4-AMINOBENZAMIDES AS KCNQ2/3 MODULATORS | KCNJ2, KCNQ2, KCNQ1 | LMNA 1359/4885POLB 4027/4885GAA 3329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.